Navigation Links
NW Bio Announces $10 Million Registered Direct Offering
Date:4/18/2013

BETHESDA, Md., April 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 17, 2013, it entered into an agreement with one healthcare-dedicated institutional investor for a registered direct placement of $10 million of common stock at the closing market price of $3.90 per share.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

In addition, the Company will issue to the investor warrant coverage of 40% to purchase shares of common stock. The warrants have an exercise price of $4.29 per share and are exercisable beginning six months after closing, with a term of five years.

The placement is expected to close on or before April 19, 2013, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-185898), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 13, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at H.C. Wainwright & Co., LLC 570 Lexington Avenue, 20th Floor, New York, NY 10022 or at placements@hcwco.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the U.S. and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Probiotic Action Announces the Discovery of Four New Foods Claiming to Have Probiotic Benefits
2. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
3. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
4. Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
5. Taylor-Wharton™ Announces Recent Appointments in its Global Operations
6. Probiotic Action Announces an Acne Treatment that may Prevent and Reduce Redness and Irritation from Acne Breakouts
7. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
8. Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
9. Probiotic Action Announces New Insight on Why Acne is a Problem for First World Citizens and Offers Advice on Treatments
10. Vestiage Announces Key Partners for Launch of Monterey Bay Nutraceuticals Anti-Aging Wellness Products
11. Probiotic Action Announces A New Natural Alternative to Expensive and harmful Acne Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November ... Business Conference will bring together over 500 top healthcare leaders for a night and ... The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, will ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... companies in the TSX Venture 50 TM . ... TSX Venture Exchange, in each of five major industry sectors ... life sciences, diversified industries and technology – based on a ... market cap growth, trading volume and analyst coverage. All data ...
Breaking Biology Technology:
(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/8/2016)... ANGELES and MANCHESTER, United Kingdom ... ("BBI"), a developer of innovative sensor-based diagnostic products, today announced ... financed by new and existing investors.  Proceeds from the financing ... SEM Scanner , a hand-held device for detecting early-stage pressure ... Ireland after receiving CE Mark approval. ...
Breaking Biology News(10 mins):